Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Albert-Ludwigs-Universität Freiburg has 7 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a distinct examiner and a distinct art unit, producing 7 separate examiner and examination-group paths.
TENTONI, LEO B is the busiest examiner, with 1 pending matter. No examiner has repeated handling in the listed data, so counsel should not assume that one examiner’s approach will carry across the docket.
Portfolio coordination should focus on consistent scientific terminology, disclosure support, and amendment discipline. Responses should remain tailored to each art unit and examiner because the matters do not share those assignments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWOCZKO, EVAN MICHAEL | 1 | — | — |
| MELLOTT, JAMES M | 1 | 51.1% | +44.1% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
| NGUYEN, PETER | 1 | — | — |
| SMALL, KATHERINE R | 1 | 69.4% | +29.6% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037945 | LIGHT-CONTROLLED VIRAL TRANSDUCTION | SMALL, KATHERINE R | 30d |
| 18702932 | METHOD FOR SPRAY COATING A SURFACE ATTACHED HYDROGEL | MELLOTT, JAMES M | 34d |
| 18701195 | INHALABLE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF FIBROTIC AUTOIMMUNE OR INFLAMMATORY LUNG DISEASES | ANDERSON, REBECCA L | — |
| 18261248 | METHOD AND SYSTEMS FOR IDENTIFYING A SEQUENCE OF MONOMER UNITS OF A BIOLOGICAL OR SYNTHETIC HETEROPOLYMER | NGUYEN, PETER | — |
| 18030875 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037945 | LIGHT-CONTROLLED VIRAL TRANSDUCTION | SMALL, KATHERINE R | 30d |
| 18702932 | METHOD FOR SPRAY COATING A SURFACE ATTACHED HYDROGEL | MELLOTT, JAMES M | 34d |
| 18701195 | INHALABLE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF FIBROTIC AUTOIMMUNE OR INFLAMMATORY LUNG DISEASES | ANDERSON, REBECCA L | — |
| 18030875 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1759 | 1 |
| 1626 | 1 |
| 1685 | 1 |
| 1633 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864510 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED RENAL CLEARANCE | LEWOCZKO, EVAN MICHAEL | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18702932 | METHOD FOR SPRAY COATING A SURFACE ATTACHED HYDROGEL | MELLOTT, JAMES M | 1759 | §103§112 | Non-Final OA | 34d | Pending | Apr 19, 2024 |
| 18701195 | INHALABLE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF FIBROTIC AUTOIMMUNE OR INFLAMMATORY LUNG DISEASES | ANDERSON, REBECCA L | 1626 | §103§112 | Final Rejection | — | Pending | Apr 12, 2024 |
| 18261248 | METHOD AND SYSTEMS FOR IDENTIFYING A SEQUENCE OF MONOMER UNITS OF A BIOLOGICAL OR SYNTHETIC HETEROPOLYMER | NGUYEN, PETER | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18037945 | LIGHT-CONTROLLED VIRAL TRANSDUCTION | SMALL, KATHERINE R | 1633 | §101§103§112 | Final Rejection | 30d | Pending | May 19, 2023 |
| 18030875 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | TOWNSLEY, SARA ELIZABETH | 1629 | §102§112 | Non-Final OA | — | Pending | Apr 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlbert-Ludwigs-Universität Freiburg has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Evan Michael Lewoczko has the most, with 1 of Albert-Ludwigs-Universität Freiburg's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
